Zygote arrest 1 (ZAR1) is a novel maternal-effect gene which is extremely important during the oocyteto-embryo transition. Comprehensive methylation analysis of tumor-specific differentially methylated regions in human malignant melanoma has recently led to the identification of non-promoter hypermethylation of the ZAR1 gene that had never been previously linked to aberrant methylation. Strikingly, ZAR1 hypermethylation was frequently observed in melanomas but was absent in benign nevi, and ZAR1 expression was found to be up-regulated in methylated tumors. The present study searched for non-promoter ZAR1 hypermethylation in 90 primary human brain tumor samples, normal brain tissue from one autopsy case, and 7 glioma cell lines, employing Sequenom MassARRAY, in which bisulfitetreated fragments are quantitatively detected using time-of-flight mass spectroscopy. ZAR1 transcript expression levels were also evaluated by quantitative real-time reverse transcription-polymerase chain reaction in the 7 glioma cell lines. Hypermethylation of ZAR1 was frequently found in diffuse astrocytomas (7/7, 100%), anaplastic astrocytomas (16/17, 94%), glioblastomas (27/29, 93%), oligodendrogliomas (3/3, 100%), anaplastic oligodendrogliomas (3/3, 100%), and pituitary adenomas (9/10, 90%), but not in pilocytic astrocytomas (0/3). Other tumor types showed infrequent ZAR1 hypermethylation: 1 (17%) of 6 vestibular schwannomas and 4 (33%) of 12 meningothelial meningiomas. The normal brain tissue revealed no evidence of ZAR1 methylation. All 7 glioma cell lines displayed aberrant hypermethylation of ZAR1, but none had detectable ZAR1 transcript. Our findings indicate that non-promoter hypermethylation of ZAR1 is extremely frequent in diffuse gliomas and pituitary adenomas, but methylation-related aberrant ZAR1 expression is far less likely to be related to glioma tumorigenesis.
Introduction
Numerous types of tumors originating from neuroepithelial or other tissues develop in the human brain. The most common human brain tumors are gliomas, which are classified as grade I to grade IV on the basis of the histological and clinical criteria established by the World Health Organization (WHO). 2) WHO grade I gliomas are well-circumscribed, slowly growing tumors, for which complete surgical resection is generally curative with malignant transformation being extremely rare. In contrast, WHO grade II or III gliomas infiltrate diffusely into the surrounding brain tissues and display an intrinsic tendency to progress to higher-grade malignancies. WHO grade IV diffuse glioma, glioblastoma, is the most aggressive and least treatable form of primary brain tumor in adults. The current standard care for glioblastoma is surgical treatment followed by adjuvant radiation therapy and novel chemotherapy with the oral alkylating agent temozolomide, but achieves a median survival of only 15 months. 10) Aberrant deoxyribonucleic acid (DNA) methylation is the most prevalent event in reversible epigenetic alterations, and has been implicated as an alternative mechanism to irreversible changes in the DNA sequence including chromosomal deletion, amplification, and somatic mutation for inactivation
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of a number of tumor suppressor genes and genes that preserve normal cellular function. In glioblastomas, for instance, frequent promoter hypermethylation has been noted for O 6 -methylguanine-DNA methyltransferase, p14 ARF , RB1, RUNX3, and Testin. [3] [4] [5] [6] [7] [11] [12] [13] Most evaluations of DNA methylation have so far concentrated on genes primarily inactivated by hypermethylation of normally unmethylated CpG islands in the promoter regions and analyzed for only a restricted set of CpG sites in their target regions. Recent evaluation of the methylation status of global genomic regions in colorectal cancer has indicated that hypermethylation of some CpG islands located in non-promoter regions does not interfere with transcriptional repression and is even associated with up-regulation or ectopic gene expression. 9) MassARRAY EpiTYPER can quantitatively analyze the methylation level through base-specific cleavage in combination with matrix-assisted laser desorption ionization time-of-flight mass spectrometry detection, and so allows quantitative measurements of the individual CpG unit methylation in large stretches of genomic DNA, where fractions with at least 5% methylated DNA can be detected in mixtures. 1) DNA methylation analysis with the Sequenom MassARRAY system was recently used to examine aberrant methylation in candidate human genomic regions identified through a mouse-skin cancer model study. 8) Differentially methylated regions were detected in the exon of zygote arrest 1 (Zar1 and ZAR1 in the mouse and humans, respectively) that had never been identified as an aberrant methylated region in any human tumors. Zar1 is the first identified oocyte-specific maternal-effect gene that functions during oocyte-to-embryo transition in mice. 14) In humans, ZAR1 expression is restricted to the ovaries and testes. Notably, hypermethylation of the off-promoter of the ZAR1 intergenic region was frequently observed in 94% of melanoma cell lines and 93% of melanoma surgical specimens, but was absent in both normal human epidermal melanocyte cell lines and melanocytic nevus surgical specimens. 8) The ZAR1 promoter regions were unmethylated in both melanoma and normal melanocytes. In part of the hypermethylated cell lines, the ZAR1 gene was over-expressed, but was either absent or extremely under-expressed in unmethylated cell lines, normal epidermal melanocyte cell lines, or fibroblast cell lines. The methylation status of ZAR1 was also analyzed in other solid types of malignant tumor cells including glioma cell lines, and found hypermethylation in all tumor cell lines examined.
The present study screened for ZAR1 non- Human malignant glioma U-87MG and U-138MG cells were purchased from American Type Culture Collection (Manassas, Va., U.S.A.), and A-172, AM-38, T98G, U-251MG, and YH-13 cells were purchased from the Health Science Research Resources Bank (Sennann, Osaka). Cells were cultured in Dulbecco's modified Eagle medium (GIBCO TM ; Invitrogen, Carlsbad, Calif., U.S.A.) supplemented with 10% fetal bovine serum (GIBCO TM ; Invitrogen) in a standard humidified incubator at 379 C under a 5% CO 2 -95% air atmosphere.
Genomic DNA was extracted from the frozen tissues and cell lines using a QIAamp DNA Mini Kit (Qiagen Inc., Valencia, Calif., U.S.A.) following the manufacturer's instructions. The total ribonucleic acid (RNA) was isolated from the glioma cell lines employing a QIA Shredder (Qiagen Inc.) and RNeasy Mini Kit (Qiagen Inc.).
II. Quantitative analysis of ZAR1 methylation by base-specific cleavage and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry Sequenom MassARRAY quantitative methylation analysis using the MassARRAY Compact System (Sequenom, San Diego, Calif., U.S.A.) was carried out for the quantitative ZAR1 methylation analysis.
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This system is based on mass spectrometry for the detection and quantitative analysis of DNA methylation employing Homogeneous MassCLEAVE (Sequenom), base-specific cleavage, and MALDI-TOF mass spectrometry. 1) Bisulfite treatment produces methylation-dependent sequence variations of C to T in the amplification products. These C/T variations appear as G/A variations in the cleavage products generated from the reverse strand by basespecific cleavage. The G/A variations result in a mass difference of 16 Da per CpG site, which is detected by the MassARRAY system. In the mass spectrum, the relative amount of methylation can be measured by comparing the signal intensity between the mass signals of methylated and non-methylated templates.
Genomic DNA was isolated, as described above. DNA (1 mg) was converted with sodium bisulfite using the EZ DNA Methylation Kit (Zymo Research, Orange, Calif., U.S.A.). The primers employed for quantitative ZAR1 methylation analysis were designed for 239 bp of the bisulfite-treated fragment for the MassARRAY EpiTYPER (Sequenom). 8) The analyzed region of ZAR1 is located 380 bp downstream from the transcription initiation site and in the middle of the first long exon. The forward primer was 5?-GGTTTTTTTTTTTAGTAGTTATTT-3? and the reverse primer was 5?-ACCTCCCCCTCC-TCTAAA-3?. The reverse primer has a T7-promoter tag for in vitro transcription (5?-CAGTAATACGAC-TCACTATAGGGAGAAGGCT-3?) and the forward primer is tagged with a 10mer to balance the temperature Tm (5?-AGGAAGAGAG-3?). Polymerase chain reaction (PCR) amplification of 1 ml bisulfite-treated DNA (¿20 ng/ml) was performed using HotStar Taq Polymerase (Qiagen Inc.) in a 5 ml reaction volume with PCR primers at a 200 nM final concentration. After shrimp alkaline phosphatase treatment, 2 ml portions of the PCR products were used as a template for in vitro transcription and ribonuclease A cleavage for the T-reverse reaction, according to the manufacturer's instructions (Homogeneous Mass-CLEAVE). The samples were desalted and spotted on a 384-pad SpectroCHIP (Sequenom) employing a MassARRAY nanodispenser, followed by spectral acquisition on a MassARRAY Analyzer Compact MALDI-TOF mass spectrometry (Sequenom). The resultant methylation calls were analyzed with EpiTYPER software v1.0 (Sequenom) to generate quantitative results for each CpG site or an aggregate of multiple CpG sites.
A standard curve for quantitative DNA methylation analysis was generated using 0%, 50%, and 100% methylated samples. 5?-Aza-deoxycytidine treatment was performed twice (on days 1 and 3) in a standard normal lymphocyte cell culture and cells were harvested on day 4 for DNA preparation of the 0% methylation samples. Two times M.Sss-1-treated DNA was prepared according to the manufacturer's protocols (New England Biolabs, Beverly, Mass., U.S.A.) at 379 C for 1 hour followed by 659 C for 20 minutes inactivation for the 100% methylation samples. An equal-amount mixture was used for the 50% methylation samples. A standard curve was fitted and the methylation levels were adjusted.
The experiments were performed in triplicate. Non-applicable readings and their corresponding sites were eliminated from the calculations.
III. Quantitative real-time reverse transcription (RT)-PCR
Quantitation of ZAR1 expression was performed by the quantitative real-time RT-PCR method, as reported previously. Briefly, single-strand complementary DNA (cDNA) was synthesized from total RNA employing a Prime Script RT Reagent Kit (Takara Bio Inc., Otsu, Shiga). The generated cDNA was amplified on a Thermal Cycler Dice } Real-Time System (Takara Bio Inc.) using SYBR Premix Ex Taq (Takara Bio Inc.). The primer sequences were ZAR1-F: 5?-ATGTGTGGTGTGTACAGGGAAC-3? and ZAR1-R: 5?-TTTTACTGGGCAGGAACATCTC-3?, and the annealing temperature was 609 C. The resultant PCR cycle-time values were collected employing the software provided for the Thermal Cycler Dice } Real-Time System. The expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene were measured using GAPDH-F: 5?-GCACCGTCAAGGCTGAGAAC-3? and GAPDH-R: 5?-TGGTGAAGACGCCAGTGGA-3? primers at an annealing temperature of 609 C. The data were used to normalize for differences in input cDNA.
IV. Immunohistochemistry
To evaluate the proliferative activity of tumor cells, MIB-1 immunohistochemistry was employed. Sections were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was blocked by incubation with 0.3% hydrogen peroxidase in methanol for 30 minutes at room temperature. After deparaffinization and rehydration, the sections were immersed in 0.01 M citrate buffer (pH 6.0) and heated in a microwave oven. Sections were then incubated at room temperature with antibody to MIB-1 (1:50, M7240; Dako Corp., Tokyo). The reaction was visualized using a Vectastain ABC kit and diaminobenzidine (Vector Laboratories, Burlingame, Calif., U.S.A.). To determine the labeling index of MIB-1, the percentage of immunoreactive tumor cell nuclei per minimum of 1000 tumor 
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cells was determined in 10 fields per preparation, and the average was calculated.
Results
DNA obtained from the 7 glioma cell lines, 90 surgical specimens, and one normal brain tissue specimen was subjected to methylation of the intergenic CpG islands in ZAR1 employing MassARRAY EpiTYPER. Representative data for the Sequenom MassARRAY analysis are presented as an epigram in Fig. 1 . The extent of methylation was measured as a percentage of the total methylation. Table 1 shows the average methylation levels for the entire target region of ZAR1 in all the samples examined.
To determine whether or not aberrant methylation of ZAR1 occurred in human brain tumors, human normal brain tissue and glioma cell lines were first studied. Notably, the normal brain tissue revealed no evidence of methylation in any of the targeted CpG sites. In contrast, the majority of CpG sites analyzed were completely methylated in all of the 7 glioma cell lines.
To assess the relevance of non-promoter hypermethylation of the ZAR1 gene in vivo, a series of primary human brain tumors were examined for aberrant ZAR1 methylation employing MassARRAY EpiTYPER. Hypermethylation was defined as the average percent methylation level for the entire target regions being more than 50%. Aberrant ZAR1 hypermethylation was found to be frequent in diffuse gliomas and pituitary adenomas, which showed aberrant hypermethylation in 57 (97%) of 59 and 9 (90%) of 10 cases, respectively. In diffuse astrocytic gliomas, aberrant hypermethylation of ZAR1 exhibited similar frequencies across the spectrum of grades: diffuse astrocytomas (grade II) had hypermethylation in 7 (100%) of 7, anaplastic astrocytoma (grade III) in 16 (94%) of 17, and glioblastomas (grade IV) in 27 (93%) of 29 cases. There was no significant difference in the frequency of ZAR1 hypermethylation between primary (23/25, 92%) and secondary (4/4, 100%) glioblastomas. In contrast, the non-promoter of ZAR1 was hypomethylated in all 3 pilocytic astrocytomas analyzed. Oligodendroglial gliomas demonstrated a similar incidence of ZAR1 hypermethylation to that seen in diffuse astrocytic gliomas: 3 (100%) of 3 oligodendrogliomas (grade II) and 3 (100%) of 3 anaplastic oligodendrogliomas (grade III). Other tumor types showed infrequent ZAR1 hypermethylation. Among the schwannomas and meningiomas tested, 1 (17%) of 6 and 4 (33%) of 12, respectively, displayed aberrant non-promoter hypermethylation of ZAR1.
The primary tumor samples were examined to measure immunohistochemical MIB-1 proliferation index. The 90 tumor samples showed a significant correlation between the MIB-1 labeling index and ZAR1 methylation status. Tumors with ZAR1 hypermethylation had a median MIB-1 labeling index of 12.5% as opposed to a median MIB-1 labeling index of 1.7% in tumors with ZAR1 hypermethylation (p º 0.001 by the Mann-Whitney U test). When ZAR1 methylation was analyzed as a continuous form, a positive correlation was also observed (p º 0.001 and r ＝ 0.433 by Pearson's correlation coefficient test). In the 59 diffuse gliomas, the extent of ZAR1 methylation revealed no correlation with the MIB-1 labeling index (p ＝ 0.757 and r ＝ 0.041 by Pearson's correlation coefficient test). Similarly, in either group of pituitary adenoma or meningioma, no significant relationship was observed between the MIB-1 labeling index and ZAR1 methylation. However, the numbers of samples were too small to perform rigorous statistical analysis (data not shown).
Whether or not non-promoter ZAR1 hypermethylation was associated with ectopic gene expression was examined. The 7 cell lines were subjected to quantitative RT-PCR to evaluate the ZAR1 expression at the messenger RNA (mRNA) level. ZAR1 transcript expression was not detected in any of the cell lines. The absolute values for the ZAR1 mRNA normalized to the level of GAPDH in U-87MG, U-138MG, A-172, AM-38, T98G, U-251MG, and YH-13 were 1.4 × 10 
Discussion
The present study demonstrated unequivocally that aberrant hypermethylation of the non-promoter region of the ZAR1 gene was implicated in a high proportion of diffuse gliomas (97%) and of pituitary adenomas (90%). These frequencies were similar to that for malignant melanomas observed previously. 8) However, hypermethylation of the ZAR1 nonpromoter was by no means a universal finding in human brain tumors in general. Other common brain tumors showed infrequent ZAR1 hypermethylation: 17% of vestibular schwannomas and 33% of meningothelial meningiomas. Thus, ZAR1 hypermethylation is specific to few types of the ectoderm-derived tumors. Coupled with data in a previous investigation demonstrating extremely frequent hypermethylation of ZAR1 in malignant melanomas, 8) these findings suggest some overlap of pathogenesis among these tumors of presumed neural crest origin.
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In diffuse gliomas, various genes have been reported to be susceptible to aberrant hypermethylation, with the highest methylated gene incidence being up to approximately 50%. [3] [4] [5] [6] [7] [11] [12] [13] Based on our results, ZAR1 has emerged as the most frequently methylated gene in diffuse gliomas to date. Of particular interest is that frequent hypermethylation of ZAR1 was evident in low-grade diffuse astrocytomas (100%), anaplastic astrocytomas (94%), glioblastomas (93%), oligodendrogliomas (100%), and anaplastic oligodendrogliomas (100%), indicating that ZAR1 hypermethylation did not differ significantly between diffuse low-grade and high-grade gliomas. Such a high incidence of ZAR1 hypermethylation in diffuse low-grade gliomas as well as in high-grade gliomas supports the view that this change may be involved in an early stage of the evolution of diffuse glioma.
In contrast, ZAR1 hypermethylation was not identified in pilocytic astrocytomas of WHO grade I, suggesting that such tumors arise from a different type of glial progenitor. This assumption is consistent with the clinical observation that pilocytic astrocytomas very rarely undergo malignant progression, and with recent data indicating that somatic mutations of the isocitrate dehydrogenase 1 gene were frequent in low-grade diffuse astrocytomas but absent in pilocytic astrocytomas. 15) Since pilocytic astrocytomas and diffuse astrocytomas can sometimes be difficult to categorize only on the basis of histopathological criteria, ZAR1 methylation tests could help to distinguish these tumors.
In the previous study examining malignant melanomas, tumor-specific DNA methylation of CpG islands located downstream from the promoter region was sometimes associated with an increased expression of the ZAR1 transcript. 8) Conversely, the presence of ZAR1 hypermethylation was not invariably concordant with aberrant ZAR1 expression. Such a discrepancy in ZAR1 expression among these hypermethylated melanomas implies that nonpromoter hypermethylation is not necessarily the primary mechanism of ZAR1 activation and further suggests that additional epigenetic alterations such as histone modification and CCCTC-binding factor may be involved in the regulation of ZAR1 expression. 8) In the present study, ZAR1 mRNA expression was not detected in any of the hypermethylated glioma cell lines, indicating that, unlike in melanomas, ZAR1 hypermethylation in gliomas does not invoke the aberrant expression of the gene. ZAR1 hypermethylation may be a secondary effect of the tumorigeneic process or a primary effect resulting in the regulation of other genetic events.
In conclusion, hypermethylation of the ZAR1 nonpromoter was found to be a frequent event in diffuse gliomas and pituitary adenomas. Ectopic ZAR1 expression was not observed in any glioma cell lines. ZAR1 hypermethylation could represent a useful tumor marker for diffuse gliomas, although ZAR1 expression is unlikely to have a tumorigeneic function. The biological functions of ZAR1 methylation and their precise roles in the pathogenesis and progression of human tumors remain to be elucidated.
